Dabur India shares in focus as US FDA issues import alert for Silvassa manufacturing plant

Shares of Dabur India, a leading FMCG company, will be in the spotlight on Friday, June 12, as the company, in its filing to stock exchanges on Thursday, said that the US FDA had inspected the company’s manufacturing plant situated at Silvassa, Dadra and Nagar Haveli, and had identified certain deficiencies on account of data integrity and maintenance lapses.

Upon conclusion of the inspection, the company, the filing said, had received inspectional observations to which responses were suitably submitted to the US FDA.

Now, pursuant to observations noted by the authority, review of the company’s responses and Establishment Inspection Report (EIR), US FDA has issued an Import Alert (IA) 66-40 on June 10, 2026, for drugs manufactured by Dabur at the aforesaid plant.

What is an import alert by USFDA?

A US FDA Import Alert is a regulatory action that allows the agency to detain products from a manufacturing facility at US ports without physically examining each shipment.

In simple terms, it means the FDA has identified concerns—such as quality control, data integrity, or manufacturing issues—at a plant and can block products made there from entering the US until the company addresses those concerns and satisfies the regulator.

Impact on financials or the company's operations

Dabur India said that there is no impact on financial, operation or other activities of the company due to this order.

“The order concerns only a small part of our manufacturing plant situated at Silvassa, Dadra and Nagar Haveli, in relation to private label products, which generates insignificant revenue for the company,” it added.

Domestic products are not covered and not impacted by this order. The aforesaid plant continues to be operational, Dabur said further.

Other key details

Dabur India added that it was continuing to engage with the US FDA authority by providing corrective and preventive action plans along with proactive and strong action on the ground to fix the identified gaps.

"In addition, multiple internal and external independent third-party testing has shown no out-of-specification or any other concerns with any of the Company’s products. We remain committed to product quality and consumer safety despite this one-off incident," it added.

Explanation for the delay in disclosure

Dabur said there is no material delay on the part of the company as it was reviewing the order and evaluating next steps in the matter.

About Dabur India

Dabur India is a fast-moving consumer goods (FMCG) company with operations spanning healthcare, personal care, and food products. Founded by Dr. S.K. Burman in 1884 as an Ayurvedic medicines business in Kolkata, the company established its first manufacturing facility in 1896.

As its operations expanded across eastern and northeastern India, Dabur set up research laboratories and additional manufacturing units. In 1936, the business was incorporated as Dabur India (Dr. S.K. Burman) Pvt. Ltd.

Today, the company markets a wide range of products across categories, including Ayurvedic medicines, health supplements, oral care, hair care, skin care, and packaged foods.